

XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

AIRO2022

Radioterapia di precisione per un'oncologia innovativa e sostenibile

BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

 Associazione Italiana
Radioterapia e Oncologia clinica

 Società Italiana di Radiobiologia

 Associazione
Italiana
Radioterapia
e Oncologia
clinica




XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI


AIRO2022

Radioterapia di precisione per un'oncologia innovativa e sostenibile

BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

EFFICACY AND SAFETY OF INTENSITY MODULATED RADIATION THERAPY IN VULVAR CANCER: DISAPPOINTING RESULTS FROM A RETROSPECTIVE SINGLE-CENTER EXPERIENCE

DR.SSA MARTINA FERIOLI



DICHIARAZIONE

Relatore: DR.SSA MARTINA FEROLI

- Posizione di dipendente in aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Consulenza ad aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Fondi per la ricerca da aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Partecipazione ad Advisory Board **(NIENTE DA DICHIARARE)**
- Titolarità di brevetti in compartecipazione ad aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**
- Partecipazioni azionarie in aziende con interessi commerciali in campo sanitario **(NIENTE DA DICHIARARE)**



INTRODUCTION

- Radiotherapy treatment in vulvar cancer is an option in the advanced disease and in the adjuvant setting (\pm chemotherapy): IMRT and VMAT to deliver higher doses and spare OARs
- 12-37% of patients relapse after initial treatment

AIM OF THE STUDY

Retrospectively analyse clinical outcomes and toxicity in patients treated in our center for vulvar cancer with IMRT and VMAT techniques

METHODS

- 41 patients treated in our center from January 2016 to December 2021: **NO patients excluded!**
- Endpoints: LC, OS, PFS and toxicity



RESULTS

Patients characteristics

- Median follow-up of 9 months (range 0-44) --- **Ten patients FU < 6 months**
- Median age: 77 years (range: 46-93)
- Adjuvant RT : 17 patients (41.5%) - Radical RT : 24 patients (58.5%)
- **20 patients (48.8%) treated on local recurrence**
- IMRT in 33 patients (80.5%), VMAT in 8 patients (19.5%)
- **2 patients did not complete the treatment due to toxicity (skin G3, GI G3)**

Acute Toxicity

- Grade 2 (22%) or 3 (73.2%) skin acute toxicity
- Gastrointestinal and genitourinary toxicities affected fewer patients (G1-2)
- G3 acute gastrointestinal toxicity affected one patient



RESULTS

Outcomes

Outcome (%)	Timing (years)	Treatment aim			p:	Vulvar cancer		p:
		All patients	Adjuvant	Radical		Primary	Recurrent	
Number of patients		41	17	24		21	20	
LC	1	68.3	81.4	58.0	.147	84.0	52.0	.045
	2	55.7	67.9	43.5		73.5	39.0	
PFS	1	66.2	71.3	54.5	.172	79.6	52.0	.040
	2	55.6	57.0	40.9		69.6	27.7	
OS	1	59.1	86.7	38.4	.019	63.5	54.6	.463
	2	38.4	52.5	27.4		50.8	25.6	

OS in radical pts	Primary	Recurrent	p
1y	37.5%	39.3%	0.456
2y	25.0%	29.5%	

OS in adjuvant pts	Primary	Recurrent	p
1y	88.9%	83.3%	0.087
2y	76.2%	20.8%	

OS in recurrent pts	Adjuvant	Radical	p
1y	83.3%	29.5%	0.388
2y	20.8%	29.5%	



DISCUSSION and CONCLUSIONS

- 53.7% of patients were older than 75 years – higher toxicity and worse compliance?
- 2 pts early stopped the treatment, 3 pts were lost at follow-up immediately after the end of RT, 7 pts died very early after treatment – altered outcomes rates?
- 41.5% of pts had nodal disease – more risk of recurrence!
- Despite IMRT allows to enhance tumor control, our data suggests that in an elderly population it is not always possible to deliver a proper treatment with satisfactory clinical outcomes and it is more difficult to eradicate recurrent disease
- Skin toxicity remains an important limitation to deliver the high doses needed to eradicate the tumor
- The need of prospective and multicentre studies



XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

AIRO2022

Radioterapia di precisione per un'oncologia innovativa e sostenibile

BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

GRAZIE PER L'ATTENZIONE

XXXII CONGRESSO NAZIONALE AIRO
XXXIII CONGRESSO NAZIONALE AIRB
XII CONGRESSO NAZIONALE AIRO GIOVANI

AIRO2022

Radioterapia di precisione per un'oncologia innovativa e sostenibile

BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

 Associazione Italiana
Radioterapia e Oncologia clinica

 Società Italiana di Radiobiologia

 Associazione
Italiana
Radioterapia
e Oncologia
clinica
